Holen Sie sich die Stockscreener-App
154.71
0.38%
0.59
Handel nachbörslich:
154.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$154.12
Offen:
$153.54
24-Stunden-Volumen:
958.58K
Relative Volume:
0.40
Marktkapitalisierung:
$36.93B
Einnahmen:
$222.29B
Nettoeinkommen (Verlust:
$1.56B
KGV:
24.14
EPS:
6.41
Netto-Cashflow:
$2.44B
1W Leistung:
+0.17%
1M Leistung:
+1.99%
6M Leistung:
+26.03%
1J Leistung:
+56.59%
1-Tages-Spanne:
$153.41
$154.84
1-Wochen-Bereich:
$153.32
$157.82
52-Wochen-Spanne:
$93.17
$157.82
Cardinal Health Inc Stock (CAH) Company Profile
Firmenname
Cardinal Health Inc
Sektor
Branche
Telefon
(614) 757-3033
Adresse
7000 CARDINAL PLACE, DUBLIN, OH
Vergleichen Sie CAH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
154.71 | 36.75B | 222.29B | 1.56B | 2.44B | 6.41 |
|
MCK
Mckesson Corporation
|
712.89 | 89.11B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
288.94 | 56.34B | 310.23B | 1.69B | 3.58B | 8.62 |
|
HSIC
Henry Schein Inc
|
70.37 | 9.00B | 12.50B | 314.00M | 421.00M | 2.44 |
|
YI
111 Inc Adr
|
8.42 | 71.51M | 2.05B | -45.99M | 5.54M | -0.5634 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-01-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-01-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-13 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-09 | Hochstufung | Argus | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Underweight |
| 2023-07-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-03-31 | Eingeleitet | Citigroup | Neutral |
| 2023-02-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-05-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-08-05 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-05-10 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-01-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-11-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-07-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-15 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-03-20 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2020-02-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-08-27 | Herabstufung | Argus | Buy → Hold |
| 2019-08-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-18 | Eingeleitet | Guggenheim | Neutral |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2018-11-16 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2018-04-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-04-02 | Hochstufung | Argus | Hold → Buy |
| 2018-03-08 | Eingeleitet | Barclays | Equal Weight |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Underperform |
| 2018-01-05 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Cardinal Health Inc Aktie (CAH) Neueste Nachrichten
Cardinal Health: Specialty Pharmaceutical Growth Glimmers But Risks Lurk (NYSE:CAH) - Seeking Alpha
Mizuho Adjusts Price Target on Cardinal Health to $161 From $150, Maintains Outperform Rating - marketscreener.com
Cardinal Health Unveils Kendall DL Multi System for Integrated Patient Monitoring - MSN
Cardinal Health: New Device Launch and Other Important Updates - TradingView
Cardinal Health: Analyst Upgrade and Other Important Updates - TradingView
Cardinal Health (NYSE:CAH) Launches Innovative Single-Patient Monitoring System to Enhance Patient Care - simplywall.st
Cardinal Health Rolls Out Kendall DL Multi Vital Signs Monitor - Medical Product Outsourcing
Cardinal Health (CAH) Launches Innovative Patient Monitoring Sys - GuruFocus
Cardinal Health launches new medical device for the continuous m - GuruFocus
Cardinal Health Launches New Medical Device For The Continuous Monitoring Of Three Essential Vital Signs In One System - marketscreener.com
Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system - marketscreener.com
Wells Fargo Upgrades Cardinal Health (CAH) Stock, Lifts PT - Insider Monkey
Cardinal Health (CAH) Receives Bullish Upgrade from Wells Fargo - GuruFocus
Cardinal Health stock, Cencora stock upgraded at Wells Fargo - Seeking Alpha
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - 01net
Medical Device Third-party Logistics Market Trends, - GlobeNewswire
Medical Device Third-party Logistics Market Trends, Opportunities, and Forecasts to 2030: Key Players Like Cardinal Health and FedEx Lead in Tech-Enabled Medical Device Logistics - Yahoo Finance
Cardinal Health (CAH) Receives Target Price Upgrade from Wells F - GuruFocus
Cardinal Health (CAH) Receives Target Price Upgrade from Wells Fargo | CAH Stock News - GuruFocus
Leerink Partners Adjusts Price Target on Cardinal Health to $177 From $173, Maintains Outperform Rating - marketscreener.com
Cardinal Health (CAH) Receives Upgrade with Higher Price Target | CAH Stock News - GuruFocus
Cardinal Health (CAH) Receives Rating Upgrade from Analyst | CAH Stock News - GuruFocus
Fortune 500: Here's how Central Ohio companies ranked in this year's list - The Business Journals
Cardinal Health, Inc. (NYSE:CAH) is favoured by institutional owners who hold 89% of the company - Yahoo Finance
Continence Care Market Size to Surpass USD 9.54 Billion by 2031 With 5.6% CAGR, Surging Prevalence of Chronic Diseases Propels the Demand | The Insight Partners - GlobeNewswire Inc.
Interesting CAH Put And Call Options For July 11th - Nasdaq
Forget UnitedHealth. Cardinal Health Is the Best Healthcare Stock to Buy Right Now - 24/7 Wall St.
Nephron Research Adjusts Cardinal Health Price Target to $166 From $160 - marketscreener.com
Baird Adjusts Price Target on Cardinal Health to $181 From $170, Maintains Outperform Rating - marketscreener.com
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook? - Yahoo Finance
Cardinal Health, Inc. (NYSE:CAH) is a favorite amongst institutional investors who own 89% - simplywall.st
Cardinal Health, Inc. (NYSE:CAH) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cardinal Health Stock: Is CAH Outperforming the Healthcare Sector? - MSN
FY2025 EPS Estimate for Cardinal Health Boosted by Analyst - Defense World
Cardinal Health ($CAH) Is Paying a $109M Settlement to Investors — Here’s How to Get Your Share - TradingView
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
Cardinal Health stock soars to all-time high of $155 By Investing.com - Investing.com South Africa
Cardinal Health stock soars to all-time high of $155 - Investing.com Australia
Jim Cramer On Cardinal Health (CAH) “They Are Impressive” - Insider Monkey
Jim Cramer On Cardinal Health (CAH) "They Are Impressive" - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail
CAH Q1 Earnings Call: Cardinal Health Misses Revenue Targets but Exceeds Profit Expectations Amid Tariff Headwinds - Yahoo Finance
Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Zacks Industry Outlook Highlights Cardinal Health, Labcorp and Align Technology - Yahoo Finance
Cardinal Health Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Cardinal Health Insiders Sold US$18m Of Shares Suggesting Hesitancy - Yahoo Finance
Cardinal Health (CAH) Faces Market Focus Amid Global Trade Talks - GuruFocus
Cardinal Health (CAH): Navigating Market Uncertainty | CAH Stock News - GuruFocus
JPMorgan Adjusts Cardinal Health Price Target to $156 From $145, Maintains Neutral Rating - marketscreener.com
Cardinal Health's (NYSE:CAH) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Cardinal Health (NYSE:CAH) Has Announced That It Will Be Increasing Its Dividend To $0.5107 - Yahoo Finance
Finanzdaten der Cardinal Health Inc-Aktie (CAH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):